Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
Provided By PR Newswire
Last update: Dec 1, 2022
INDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
Read more at prnewswire.com
